首页> 美国卫生研究院文献>Polish Journal of Microbiology >Evaluation of a Salmonella Strain Isolated from Honeybee Gut as a Potential Live Oral Vaccine Against Lethal Infection of Salmonella Typhimurium
【2h】

Evaluation of a Salmonella Strain Isolated from Honeybee Gut as a Potential Live Oral Vaccine Against Lethal Infection of Salmonella Typhimurium

机译:从蜜蜂肠道分离的沙门氏菌菌株作为针对伤寒沙门氏菌致死性感染的潜在口服活疫苗的评价

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

In this research, species were isolated from the animal, insect and human enteric sources in Faisalabad, Punjab, Pakistan. These species were characterized by different microbiological and molecular techniques including polymerase chain reaction (PCR) by amplification of the 16S rRNA gene. Furthermore, sequencing of the amplicons confirmed all ten isolates as strains. The antigenic cross-reactivity was found maximum between the HB1 (strain isolated from honeybee) antiserum and its antigen with an antibody titer of 1:128, while the HB1 antiserum showed a cross-reactive titer range of 1:8 to 1:64. On the basis of the highest geometric mean titer (GMT) shown by the antiserum of the HB1 antigen, it was selected as the best candidate for a cross-reactive live oral antigen. Moreover, the HB1 antigen was used a live oral antigen (1 × 10 CFU/ml) in a safety test in rabbits and proved to be avirulent. During the animal trial, three different oral doses of the HB1 live oral antigen were evaluated in four different rabbits’ groups (R1, R2, R3, and R4). The dose number 2 of 0.5 ml (two drops orally and repeated after one week) gave the best GMT measured by indirect hemagglutination (IHA) as compared to the other two doses, while R4 group was kept as control. Results of the challenge protection test also validated the efficacy of the double dose of the HB1 live vaccine, which gave the highest survival percentage. Results of this study lay the foundation for a potential cross-reactive live oral vaccine that has proved to be immunogenic in rabbits.
机译:在这项研究中,从巴基斯坦旁遮普邦的费萨拉巴德的动物,昆虫和人类肠源中分离出了物种。这些物种的特征是通过不同的微生物和分子技术,包括通过扩增16S rRNA基因的聚合酶链反应(PCR)。此外,扩增子的测序证实所有十个分离株均为菌株。发现抗原交叉反应在HB1(从蜜蜂分离的菌株)和其抗原之间的抗体效价为1:128最大,而HB1抗血清的交叉反应效价范围为1:8至1:64。根据HB1抗原抗血清显示的最高几何平均滴度(GMT),它被选为交叉反应性口服活性抗原的最佳候选者。此外,在兔子的安全性测试中,HB1抗原被用作活体口服抗原(1×10 CFU / ml),并被证明是无毒的。在动物试验期间,在四个不同的兔子组(R1,R2,R3和R4)中评估了三种不同剂量的HB1活口服抗原。 0.5 ml的剂量2(口服2滴,一周后重复)与其他2剂相比,通过间接血凝(IHA)测得的GMT最好,而R4组则作为对照组。攻击保护测试的结果还验证了双剂量HB1活疫苗的功效,该疫苗具有最高的存活率。这项研究的结果为潜在的交叉反应活性口服疫苗奠定了基础,该疫苗已证明对兔具有免疫原性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号